Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.79 |
| ▸ | GNAI3 | P08754 | 9/20 | 0.68 |
| ▸ | GNAI1 | P63096 | 9/20 | 0.68 |
| ▸ | GNAO1 | P09471 | 8/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14879738 | 0.98 | NPC1 (0.76) | NPC1GNAI3GNAI1GNAO1L3MBTL1 | |
| SCHEMBL3365303 | 0.98 | NPC1 (0.76) | NPC1GNAI3GNAI1GNAO1L3MBTL1 | |
| SCHEMBL9062091 | 0.94 | NPC1 (0.81) | NPC1GNAI3GNAI1GNAO1L3MBTL1 | |
| SCHEMBL11546458 | 0.89 | NPC1 (0.63) | NPC1GNAI3GNAI1GNAO1L3MBTL1 | |
| SCHEMBL11546455 | 0.89 | NPC1 (0.63) | NPC1GNAI3GNAI1GNAO1L3MBTL1 | |
| SCHEMBL20034969 | 0.88 | MEN1 (0.71) | NPC1GNAI3GNAI1GNAO1L3MBTL1 | |
| SCHEMBL10274470 | 0.86 | NPC1 (0.74) | NPC1GNAI3GNAI1GNAO1L3MBTL1 | |
| SCHEMBL7490420 | 0.85 | GNAI3 (0.68) | NPC1GNAI3GNAI1GNAO1L3MBTL1 | |
| SCHEMBL2134122 | 0.84 | L3MBTL1 (0.83) | NPC1GNAI3GNAI1GNAO1L3MBTL1 | |
| SCHEMBL6285463 | 0.84 | L3MBTL1 (0.83) | NPC1GNAI3GNAI1GNAO1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242548-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242548-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | NPC1 2113/4885GNAI3 209/4885GNAI1 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.